Solution Delivery TRIZ Cases

PET/CT uptake screening guides Copper-64 dosing and patient selection, improving biodistribution control in cancer treatment.

Using mRNA and lipid nanoparticles, this case shows how cancer vaccines avoid DNA integration while producing earlier, stronger immune responses.

A core-shell polymer and cellulose shell resists stomach acid yet disintegrates at intestinal pH, avoiding thick enteric coatings.

Droplet evaporation under Peclet number control forms circular therapeutic particles with low internal voids, stable structure, and tunable surface enrichment.

A fluidic dilution approach creates radiopharmaceutical batches with matched activity at different application times from one calibrated bulk solution.

Ascorbate-based 177Lu-PSMA I&T synthesis limits radiolysis, delivering high purity and multi-day stability during storage at 30°C.

Sequential gentisic acid and ascorbic acid stabilization enables concentrated radionuclide solutions with 3-day shelf life and ready-to-use dosing.

Cyclodextrin co-stabilization helps radiopharmaceuticals resist radiolysis and maintain radiochemical purity at high radioactive concentrations.

Buffered pH 7.0-8.9 with ascorbic acid helps 225Ac radiopharmaceuticals resist radiolysis and stay above 91% purity for 168 hours.

Sequential gentisic acid and ascorbic acid stabilization enables concentrated radionuclide solutions that stay stable in storage and ship ready to use.

Sequential gentisic acid and ascorbic acid addition limits radiolytic degradation in concentrated radionuclide solutions for 72-hour ready-to-use storage.

A bulk-solution dilution approach keeps radiopharmaceutical activity and composition consistent across different application times in one fill process.

By lowering lipophilicity, this F-18 α-synuclein PET tracer crosses the blood-brain barrier and reduces non-specific binding in Parkinson's lesion imaging.

Sequential gentisic acid and ascorbic acid stabilization keeps concentrated radionuclide solutions stable for shipment and ready-to-use dosing.

High-load cyclosporin is stabilized in aqueous nanodroplets using non-ionic surfactants to improve ocular delivery with minimal irritation.

Adding a reducing agent raises radiochemical purity in astatine-211 solutions and improves thyroid radioactivity accumulation.

Low radiochemical purity weakens thyroid accumulation; a physiologically acceptable reducing agent converts oxidized astatine to 211At−.

Staged gentisic acid and ascorbic acid stabilization protects concentrated GRP receptor peptide complexes from radiolytic degradation during storage.

Optimized PSMA I&T-to-177Lu ratios lower absorbed radiation in healthy organs while supporting longer prostate cancer treatment cycles.

The 3.0:1.0–8.0:1.0 PSMA I&T-to-177Lu range supports at least 95% radiochemical purity while reducing absorbed radiation in healthy organs.

This case adjusts ligand-to-radiometal ratios and formulation conditions to preserve purity while lowering healthy-organ dose.

MamC templates dispersed magnetite BMNPs that balance particle size, magnetic response, surface charge, and targeted drug release.

A pH range of 7.0–8.9 improves radiochemical yield and purity, extending [225Ac]Ac-DOTA-satoreotide shelf-life.

Amphiphilic block copolymers eliminate lag phases in sustained release profiles by controlling bioactive agent diffusion through precise emulsion processing.

Oily dispersion of dezocine analogue ester particles overcomes low solubility and short half-life, enabling stable sustained release.

Alginic acid gels in acidic stomach environments to prevent gastroesophageal reflux while maintaining low viscosity for tube feeding.

Polylactic acid derivatives form stable micelles to solubilize poorly water-soluble drugs.

Adjusting pH to 2.0-4.5 before heating to 60-200°C dissolves high-temperature contrast agents while keeping free iodide levels below 30 μgI/ml.

A 3D printing process deposits flowable building substances as discrete spots to create semi-solid pharmaceutical dosage forms.

Rapid cooling below transition temperatures reduces coalescence and maintains monodispersity at high flow rates.

BAB-type tri-block copolymer forms stable micelles to encapsulate poor-soluble drugs without toxic crosslinkers.

Injecting a conductive polymer into fibrotic regions bridges electrical gaps, resolving conduction reliability issues in arrhythmia treatment.

Protocatechuic acid crystals physically disrupt viral envelopes through sharp protrusions and low pH to inactivate enveloped viruses.

Melt solidification creates stable PEG particle dispersions that resolve the contradiction between high viscosity requirements and dispersion stability.

BIOSAS process disperses bioactive compounds into lipid matrices using supercritical carbon dioxide as an antisolvent.

Tyrosine hydroxylase inhibitors and melanin promoters alter cancer cell defenses to increase oxidative stress.

Anhydrous oil suspensions stabilize pyrimethamine particles using surfactants, resolving solubility and stability contradictions.

A composite polymer matrix combining polyvinyl alcohol grades with different hydrolysis degrees facilitates stable amorphous solid dispersion formation.

Temperature-sensitive hydrogel particles expand in response to body heat, controlling swelling and therapeutic agent release during embolization.